Focused On-demand Library for Zona pellucida sperm-binding protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q05996

UPID:

ZP2_HUMAN

Alternative names:

Zona pellucida glycoprotein 2; Zona pellucida protein A

Alternative UPACC:

Q05996; B2R7J2; Q4VAN9; Q4VAP0; Q4VAP1

Background:

Zona pellucida sperm-binding protein 2, also known as Zona pellucida glycoprotein 2 or Zona pellucida protein A, plays a crucial role in fertilization. It is a component of the zona pellucida, an extracellular matrix that surrounds oocytes. This protein mediates critical processes such as sperm binding, induction of the acrosome reaction, and prevention of post-fertilization polyspermy, primarily acting as a secondary sperm receptor.

Therapeutic significance:

The protein is linked to Oocyte/zygote/embryo maturation arrest 6, an autosomal recessive infertility disorder characterized by oocyte fertilization failure. Understanding the role of Zona pellucida sperm-binding protein 2 could open doors to potential therapeutic strategies for treating infertility issues related to sperm-binding abnormalities.